Durect soars on $202M pact and new trial data

Shares of Durect soared more than 50 percent in overnight trading after the drug developer announced a $202 million pact to develop a new post-operative pain medication with Denmark's Nycomed. The two will develop Posidur using Durect's delivery system. Durect gains $14 million up front and up to $188 million in milestone payments. Posidur is expected to begin a Phase III trial next year. Durect's stock was further helped this morning when the company announced that its Phase I trial for Oradur demonstrated that the abuse-resistant pain medication was safe and well tolerated. The licensee for Oradur--Pain Therapeutics--made the announcement.

- here's the report from MarketWatch on the new pact
- and here's the AP report on the trial data

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.